ADC Therapeutics SA Basic Shares Outstanding (Weighted Average)
ADC Therapeutics SA (ADCT) reported Basic Shares Outstanding (Weighted Average) of 155.02 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-13
- ADC Therapeutics SA weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 155.02M shares, a 36.29% increase year-over-year.
- ADC Therapeutics SA weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 154.14M shares, a 43.79% increase year-over-year.
- ADC Therapeutics SA weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 150.56M shares, a 42.77% increase year-over-year.
- ADC Therapeutics SA weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 136.45M shares, a 30.17% increase year-over-year.
- ADC Therapeutics SA weighted average number of shares outstanding, basic for fiscal 2025 was 127.07M shares, a 30.78% increase from fiscal 2024.
- ADC Therapeutics SA weighted average number of shares outstanding, basic for fiscal 2024 was 97.16M shares, a 18.91% increase from fiscal 2023.
- ADC Therapeutics SA weighted average number of shares outstanding, basic for fiscal 2023 was 81.71M shares, a 4.55% increase from fiscal 2022.
- ADC Therapeutics SA weighted average number of shares outstanding, basic for fiscal 2022 was 78.15M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 155.02M shares 10-Q · filed 2026-08-13 | 154.58M shares 10-Q · filed 2026-08-13 | 153.24M shares derived: average of 3 quarters · filed 2026-08-13 | 149.04M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 154.14M shares 10-Q · filed 2026-05-04 | 152.35M shares derived: average of 2 quarters · filed 2026-05-04 | 147.05M shares derived: average of 3 quarters · filed 2026-05-04 | 138.72M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | 150.56M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 143.50M shares derived: average of 2 quarters · filed 2026-03-10 | 133.58M shares derived: average of 3 quarters · filed 2026-08-13 | 127.07M shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 136.45M shares 10-Q · filed 2025-11-10 | 125.09M shares derived: average of 2 quarters · filed 2026-08-13 | 119.24M shares 10-Q · filed 2025-11-10 | 115.71M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | 113.74M shares 10-Q · filed 2026-08-13 | 110.49M shares 10-Q · filed 2026-08-13 | 108.80M shares derived: average of 3 quarters · filed 2026-08-13 | 107.81M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | 107.20M shares 10-Q · filed 2026-05-04 | 106.33M shares derived: average of 2 quarters · filed 2026-05-04 | 105.83M shares derived: average of 3 quarters · filed 2026-05-04 | 103.29M shares derived: average of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | 105.46M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 105.14M shares derived: average of 2 quarters · filed 2026-03-10 | 101.99M shares derived: average of 3 quarters · filed 2026-03-10 | 97.16M shares 10-K · filed 2026-03-10 |
| 2024-09-30 | 104.82M shares 10-Q · filed 2025-11-10 | 100.26M shares derived: average of 2 quarters · filed 2025-11-10 | 94.39M shares 10-Q · filed 2025-11-10 | 91.34M shares derived: average of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | 95.69M shares 10-Q · filed 2025-08-12 | 89.12M shares 10-Q · filed 2025-08-12 | 86.85M shares derived: average of 3 quarters · filed 2025-08-12 | 85.70M shares derived: average of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | 82.55M shares 10-Q · filed 2025-05-14 | 82.43M shares derived: average of 2 quarters · filed 2025-05-14 | 82.37M shares derived: average of 3 quarters · filed 2025-05-14 | 82.14M shares derived: average of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | 82.30M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 82.28M shares derived: average of 2 quarters · filed 2025-03-27 | 82.01M shares derived: average of 3 quarters · filed 2025-03-27 | 81.71M shares 10-K · filed 2025-03-27 |
| 2023-09-30 | 82.26M shares 10-Q · filed 2024-11-07 | 81.86M shares derived: average of 2 quarters · filed 2024-11-07 | 81.52M shares 10-Q · filed 2024-11-07 | |
| 2023-06-30 | 81.47M shares 10-Q · filed 2024-08-06 | 81.14M shares 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | 80.81M shares 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | 78.15M shares 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |